• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Awaiting Bernanke's Impact? Keep Waiting


A lot is riding on next week's data, particularly Friday's August jobs report, which will likely keep stocks in tentative mood. August's jobs report could determine whether or not the Fed decides on another round of quantitative easing.

This article was originally published by

Ben Bernanke's much-anticipated Jackson Hole speech will determine the outcome of today's trading action. But with trading volumes expected to remain thin ahead of the long Labor Day weekend, it will probably be appropriate to not draw any firm conclusions whichever way the market closes today. Along those same lines, I am not reading much into the Thursday pullback, either.

With the next Federal Open Market Committee (FOMC) meeting just two weeks away and the key monthly jobs report on deck for release next Friday, the Fed chairman will likely stay away from making firm commitments, particularly on the central quantitative easing (QE) question.

That said, he may decide to share his views on a key question that has been swirling around lately. And this pertains to his assessment of current economic conditions and the outlook for the back half of the year. This has become important following the relatively stronger economic readings since the last FOMC meeting.

The FOMC members appeared to have a pronounced dovish bias in its last meeting, but that was a function of their downbeat economic outlook. One could reasonably assume that the positive jobs report and a couple of other key economic data points after that meeting may have made the FOMC's outlook less accommodative.

The significance of next Friday's August jobs report therefore increases significantly. I would think that a significantly sub-100,000 job reading next Friday will materially increase the odds of more Fed easing in the September meeting. On the other hand, a 100,000-plus jobs report will take the QE question off the table, at least from the September FOMC meeting.

It would make sense for the Fed to keep its “powder” dry as the fall months promise to unleash a number of destabilizing forces for the U.S. economy. The eurozone question was on summer vacation this month, but will likely be back at “work” with full vigor next month. Many expect the European Central Bank to come out with a detailed bond-purchase program at its meeting next week. But given continued German opposition, it is hardly certainty at this stage.

On the home front, the “Fiscal Cliff” question will remain unaddressed in the noise of the election season. Another round of Fed QE will have little relevance to the economy's current growth trajectory. But it could be useful in an environment where the European or the “Fiscal Cliff” issue has seriously escalated.

As such, those hoping for clear signals or prompt action from Bernanke today will likely be disappointed. A lot is riding on next week's data, particularly Friday's August jobs report, which will likely keep stocks in tentative mood.

Sheraz Mian is the Director of Research at Zacks Investment Research where he relies on valuable data to assess winning stocks and funds.

The information supplied above by Zacks Investment Research Inc. contains opinions based on factual research which may or may not be accurate. Neither Zacks nor Intellisphere will assume any liability for losses from investment decisions based on this information.

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice